Vascular Dysfunction in a Transgenic Model of Alzheimer's Disease: Effects of CB1R and CB2R Cannabinoid Agonists.
There is evidence of altered vascular function, including cerebrovascular, in Alzheimer's disease (AD) and transgenic models of the disease. Indeed vasoconstrictor responses are increased, while vasodilation is reduced in both conditions. β-Amyloid (Aβ) appears to be responsible, at least in part, of alterations in vascular function. Cannabinoids, neuroprotective and anti-inflammatory agents, induce vasodilation bothin vivoandin vitro. We have demonstrated a beneficial effect of cannabinoids in models of AD by preventing glial activation. In this work we have studied the effects of these compounds on vessel density in amyloid precursor protein (APP) transgenic mice, line 2576, and on altered vascular responses in aortae isolated ring. First we showed increased collagen IV positive vessels in AD brain compared to control subjects, with a similar increase in TgAPP mice, which was normalized by prolonged oral treatment with the CB1/CB2 mixed agonist WIN 55,212-2 (WIN) and the CB2 selective agonist JWH-133 (JWH). In Tg APP mice the vasoconstriction induced by phenylephrine and the thromboxane agonist U46619 was significantly increased, and no change in the vasodilation to acetylcholine (ACh) was observed. Tg APP displayed decreased vasodilation to both cannabinoid agonists, which were able to prevent decreased ACh relaxation in the presence of Aβ. In summary, we have confirmed and extended the existence of altered vascular responses in Tg APP mice. Moreover, our results suggest that treatment with cannabinoids may ameliorate the vascular responses in AD-type pathology.
Department of Pharmacology, School of Medicine, Complutense University of Madrid Madrid, Spain.
Jorge
J
Navarro-Dorado
Department of Physiology, Faculty of Pharmacy, Complutense University of Madrid Madrid, Spain.
Nuria
N
Villalba
Department of Physiology, Faculty of Pharmacy, Complutense University of Madrid Madrid, Spain.
Dolores
D
Prieto
Neurodegeneration Group, Cellular, Molecular and Developmental Neurobiology and CIBERNED, Cajal Institute, CSIC Madrid, Spain.
Begoña
B
Brera
Neurodegeneration Group, Cellular, Molecular and Developmental Neurobiology and CIBERNED, Cajal Institute, CSIC Madrid, Spain.
Ana M
AM
Martín-Moreno
Department of Pharmacology, School of Medicine, Complutense University of Madrid Madrid, Spain.
Teresa
T
Tejerina
Neurodegeneration Group, Cellular, Molecular and Developmental Neurobiology and CIBERNED, Cajal Institute, CSIC Madrid, Spain.
María L
ML
de Ceballos
Alzheimer's disease; Tg APP; cannabinoid receptors; collagen IV; vascular dysfunction; β-amyloid
Nature. 2000 Mar 2;404(6773):84-7
10716447
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367 (1607):3216-28
23108541
Science. 1996 Oct 4;274(5284):99-102
8810256
Br J Pharmacol. 2010 Jun;160(3):467-79
20590558
Br J Pharmacol. 2014 Mar;171(6):1361-78
24329566
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63
23108552
Neuropharmacology. 2013 Jan;64:389-95
22687521
Nat Neurosci. 1999 Feb;2(2):157-61
10195200
Science. 2002 Jul 19;297(5580):353-6
12130773
J Neuroimmune Pharmacol. 2015 Jun;10(2):268-80
25601726
Cerebrovasc Dis. 2002;13 Suppl 2:48-52
11901243
J Pharmacol Exp Ther. 1998 Feb;284(2):644-50
9454810
Acta Neuropathol. 2010 Sep;120(3):287-96
20623294
Neuroscience. 1999;93(3):969-75
10473261
Neuroscience. 1998 Mar;83(2):393-411
9460749
Br J Pharmacol. 2011 Aug;163(7):1365-78
21545415
Hypertension. 2012 Jul;60(1):188-97
22615109
J Neurosci. 2005 Feb 23;25(8):1904-13
15728830
Cell Mol Neurobiol. 2016 Mar;36(2):219-32
26993506
Naunyn Schmiedebergs Arch Pharmacol. 2014 Feb;387(2):175-84
24185999
J Neuroinflammation. 2012 Jan 16;9:8
22248049
Hypertension. 1996 Oct;28(4):682-6
8843898
FEBS Lett. 1994 Aug 22;350(2-3):240-4
8070571
Clin Sci (Lond). 2007 Dec;113(11):427-34
17531005
Am J Pathol. 2005 Aug;167(2):505-15
16049335
Am J Pathol. 2001 Mar;158(3):1065-71
11238054
Am J Hum Genet. 1999 Sep;65(3):664-70
10441572
Nature. 2002 Aug 1;418(6897):530-4
12152079
Bioorg Med Chem. 1999 Dec;7(12):2905-14
10658595
Br J Pharmacol. 2008 Jan;153(2):216-25
17891163
Nature. 1996 Mar 14;380(6570):168-71
8600393
J Cardiovasc Pharmacol. 2004 Nov;44(5):517-9
15505486
Neurobiol Aging. 2013 Mar;34(3):791-804
22795792
Biol Psychiatry. 2016 Apr 1;79(7):604-12
26852073
Neurosci Lett. 1998 Nov 27;257(2):77-80
9865931
Curr Vasc Pharmacol. 2008 Oct;6(4):335-46
18855721
Neuroscience. 2015 Dec 17;311:253-67
26515747
Front Aging Neurosci. 2014 Sep 19;6:251
25285078
Br J Pharmacol. 2007 Nov;152(5):576-82
17704824
Ann N Y Acad Sci. 2000 Apr;903:83-8
10818492
Neurosci Lett. 2004 Aug 5;366(1):80-5
15265595
J Neurosci. 2005 Nov 30;25(48):11165-74
16319316
J Neuroinflammation. 2011 Mar 25;8:26
21439035
Neuroscience. 2000;97(3):505-19
10828533
Br J Pharmacol. 2016 Jun;173(12 ):1899-910
27077495
High Blood Press Cardiovasc Prev. 2016 Mar;23 (1):3-7
26054481
Neuroscience. 2008 Mar 27;152(3):734-40
18313855
Br J Pharmacol. 2001 Jun;133(3):445-53
11375262
J Biol Chem. 2002 Sep 27;277(39):36527-33
12133838
Acta Neuropathol. 1980;49(1):79-83
7355675
Front Pharmacol. 2014 Mar 05;5:37
24634659
Br J Pharmacol. 2004 May;142(1):20-6
15131000
Exp Neurol. 1998 Mar;150(1):159-68
9514824
Ann Med. 1996 Jun;28(3):255-8
8811169
Neurosci Lett. 1999 Jun 11;268(1):17-20
10400067
Pharmacology. 2014;94(1-2):1-12
25171128
Pharmacol Rev. 2002 Jun;54(2):161-202
12037135